Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2022 Sep;60(9):1067-1069.
doi: 10.1080/15563650.2022.2084406. Epub 2022 Jun 16.

Identification of a novel opioid, N-piperidinyl etonitazene (etonitazepipne), in patients with suspected opioid overdose

Affiliations
Multicenter Study

Identification of a novel opioid, N-piperidinyl etonitazene (etonitazepipne), in patients with suspected opioid overdose

Diane P Calello et al. Clin Toxicol (Phila). 2022 Sep.

Abstract

Background: Novel opioids in the illicit drug supply, such as the "nitazene" group of synthetic opioids, present an ongoing public health problem due to high potency and respiratory depressant effects. We describe three patients in whom N-piperidinyl etonitazene, a compound not previously reported in human exposure, was detected after suspected opioid overdose. Other substances that these patients tested for included fentanyl, cocaine, levamisole, phenacetin, benzoylecgonine, para-fluorofentanyl, presumptive heroin (tested as 6-monoacetylmorphine (6-MAM), morphine, and codeine), and tramadol.

Methods: This is a case series of patients with acute opioid overdose enrolled in an ongoing multicenter prospective cohort study. Data collected included reported substance use, clinical course, naloxone dose and response, outcome, and analytes detected in biological samples.

Results: Between October 6, 2020 and October 31, 2021, 1006 patients were screened and 412 met inclusion criteria. Of these, three patients (age 33-55) tested positive for N-piperidinyl etonitazene at one site in New Jersey over a period of three days in July 2021. Two patients reported the use of cocaine; one reported the use of heroin and alprazolam. All three patients received naloxone with improvement in their mental status (2 milligrams (mg) intranasally (IN); 8 mg IN; 0.08 mg intravenous (IV)). Two of three received subsequent doses for recurrence of opioid toxicity (0.4-0.6 mg IV). One patient was diagnosed with pneumonia and admitted to the intensive care unit, one was discharged from the Emergency Department (ED), and one used additional drug while in the ED and required admission for a naloxone infusion. None developed organ damage or sequelae.

Conclusion: These cases represent a local outbreak of a novel "nitazene" opioid. Public health toxicosurveillance should incorporate routine testing of this emerging class of synthetic compounds in the illicit drug supply.

Keywords: Opioids; adulterants; analytical toxicology; novel psychoactives; toxicosurveillance.

PubMed Disclaimer

References

    1. ) Vandeputte MM, Uytfanghe KV, Layle NK, et al. Synthesis, chemical characterization, and μ-opioid receptor activity assessment of the emerging group of “nitazene” 2-benzylbenzimidazole synthetic opioids. ACS Chem Neurosci. 2021;12:1241–1251. doi: 10.1021/acschemneuro.1c00064 - DOI - PubMed
    1. ) Krotulski AJ, Papsun DM, Kacinko SL, Logan BK. Isotonitazene quantitation and metabolite discovery in authentic forensic casework. J Anal Toxicol. 2020;44:521–530. doi: 10.1093/jat/bkaa016 - DOI - PubMed
    1. ) Krotulski AJ, Papsun SE, Logan BK. Metonitazene in the United States – Forensic toxicology assessment of a potent new synthetic opioid using liquid chromatography mass spectrometry. Drug Test Anal. 2021;13(10):1697–1711. doi: 10.1002/dta.3115 - DOI - PubMed
    1. ) Walton SE, Krotulski AJ, Logan BK. A forward-thinking approach to addressing the new synthetic opioid 2-Benzylbenzimidazole nitazene analogues by liquid chromatography tandem quadrupole mass spectrometry (LC-QQQ-MS). J Anal Toxicol. 2021. doi: 10.1093/jat/bkab117 - DOI - PMC - PubMed

Publication types